Allorin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allorin

Allorin: Defining Its Identity and Classification

Property Description
Active ingredient Allopurinol
Form Oral tablet
Pharmacological class Xanthine Oxidase Inhibitor (Uricostatic)
Common purpose Long-term management of high uric acid levels
Origin Synthetic compound

Allorin is a prescription-only medication primarily identified by its active ingredient, Allopurinol, which is a synthetic compound chemically classified as an oxypurine analog. It is clinically recognized and classified as a Xanthine Oxidase Inhibitor and antigout agent. This classification confirms the drug's role in managing chronic metabolic issues. Allopurinol is the core component found in popular equivalent products, such as Zyloprim and Lopurin, sharing the same oral tablet dosage form and single-ingredient status.

Composition and General Purpose

The medication is fundamentally composed of the active ingredient Allopurinol and necessary pharmaceutical excipients used to manufacture the stable tablet. Its origin is confirmed as a synthetic compound, contrasting with natural or biologically derived therapies. As a systemic therapy, Allorin's general purpose is the long-term management of conditions arising from elevated uric acid levels, known as hyperuricemia. Allopurinol acts by reducing the amount of uric acid produced by the body. This mechanism provides the sustained metabolic control crucial for preventing crystal deposition over time. Its typical use involves a patient requiring ongoing stability of urate levels to prevent recurring issues.

Regulatory References

  1. WHO Model List of Essential Medicines - Allopurinol
  2. MedlinePlus Allopurinol Drug Information

What side effects are possible with Allorin?

Possible Side Effects and Safety Information

The safety profile of Allorin (Allopurinol) is based on classifications from official regulatory documents. Adverse reactions are grouped by the body system affected and their reported frequency.


Documented Frequency and System-Organ Classes

The most commonly reported effects include skin rash, nausea, and diarrhea, often classified as common in official prescribing information. Other common effects include elevations in liver enzyme levels and a risk of renal failure/insufficiency. Reactions are grouped into System-Organ Classes (SOC) that include Dermatological, Gastrointestinal, Hepatobiliary, and Renal systems.

Serious Adverse Reactions

Allopurinol is associated with rare but serious cutaneous events, collectively known as Severe Cutaneous Adverse Reactions (SCARs). These include Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Other serious events include cases of hepatotoxicity and myelosuppression (bone marrow suppression), which are formally documented.


Population and Time-Related Safety

An increased incidence of acute gout attacks (flares) is documented during the early stages of administration. Patients with renal impairment require lower doses to manage the risk of hypersensitivity reactions. Furthermore, regulatory documents highlight a genetic safety concern: individuals who carry the *HLA-B58:01 allele** have a significantly heightened risk of developing severe skin reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Allorin (Allopurinol) is defined in regulatory documents by specific manifestations affecting the gastrointestinal system and central nervous system. Officially documented symptoms of massive ingestion include nausea, vomiting, diarrhea, and dizziness.

The official label specifies that no specific antidote is known for Allopurinol overdose. Management is based on the administration of general supportive measures in a controlled medical environment. Procedural steps such as renal dialysis are technically feasible for removing the compound and its metabolite, oxipurinol, although its clinical utility for acute overdose management is stated as currently unknown in regulatory documentation. Monitoring of oxipurinol concentrations may be necessary to guide management where drug accumulation is suspected.

The most severe risk is the potential for life-threatening toxicity linked to massive overdose in patients receiving concurrent mercaptopurine or azathioprine. This specific interaction, or any suspected overdose, mandates that professional medical care be sought immediately. Regulatory documents also highlight that the risk of accumulation and toxicity is increased in patients with impaired renal function due to reduced clearance of the active metabolite.

Therapeutic Uses of Allorin

Allorin (Allopurinol) is commonly used to help with symptoms related to systemic imbalance and is applied across domains where additional symptomatic support is needed. Its primary therapeutic goal is relevant for easing symptoms associated with acute or episodic changes and conditions where symptoms may intensify temporarily. It is commonly used to help with gout, hyperuricemia from chemotherapy, and conditions involving recurrent kidney stones.

This medication is used for managing conditions characterized by episodic or fluctuating manifestations. It helps with the prevention of recurrent gout attacks, addresses the formation of tophi (urate deposits), and supports the management of conditions that contribute to the painful formation of uric acid stones in the urinary tract. The treatment is commonly used in clinical settings that involve heightened systemic burden, such as during cancer therapy, to manage the risk of Tumor Lysis Syndrome (TLS).

“This preventative approach contributes to improved comfort during periods of heightened symptoms, and assists with maintaining functional stability when symptoms are more noticeable.”


QuickFact Block

Quick Fact: Relief for [Symptom] Therapeutic Focus
Recurrent Joint Pain May assist with the prevention of inflammatory flare-ups associated with chronic gout.
Urologic Discomfort Supports the management of conditions that contribute to the painful formation of uric acid stones.
Systemic Risk (TLS) Contributes to supportive relief in high-risk scenarios involving rapid cell turnover.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Regulatory documents define eligibility for Allorin (allopurinol) by specifying contraindications and populations requiring special consideration.

Populations Excluded or Restricted

Classification Who Must Not Use (or Use is Restricted)
Contraindicated Individuals with a documented history of hypersensitivity to allopurinol or any component of the formulation.
Genetic Restriction Patients who test *positive for the HLA-B58:01 allele**, particularly those of Han Chinese, Thai, or Korean descent, due to significantly increased risk of severe skin reactions.
Age Restriction Children are generally restricted from use, except in cases of hyperuricemia secondary to malignancy or Lesch-Nyhan syndrome, where safety and effectiveness have been established.
Clinical State Asymptomatic hyperuricemia (high uric acid levels without symptoms/complications) is not an approved indication for use.
Physiological State Pregnancy and Lactation (Breastfeeding) are generally not recommended, as the active substance passes into breast milk and safety in these states has not been established.
Organ Impairment Patients with renal impairment (kidney disease) or hepatic impairment (liver disease) are eligible, but require dose reductions and close monitoring due to altered drug clearance.

General Eligibility

The medicine is approved for use in adults and, under strict conditions, in pediatric patients, provided no absolute contraindications or restrictions apply.

What should I know about interactions with other medicines?

Allorin Interactions with other medicines and products

Official regulatory documents detail specific pharmacokinetic and pharmacodynamic interactions for Allorin (Allopurinol) that impact co-administered medications and carry formal use restrictions.

Classification Interacting Substance/Class Official Regulatory Constraint
Contraindicated Combination Pegloticase Allopurinol therapy must be discontinued and not instituted during treatment with this agent.
Metabolic/Exposure Altering Azathioprine / Mercaptopurine These medicines require a dose reduction to approximately one-third to one-fourth of the usual dose due to inhibited metabolism, which increases their plasma concentration.
Exposure Monitoring Required Coumarin Anticoagulants (e.g., Warfarin) Allopurinol may prolong the half-life of these anticoagulants, enhancing their effect and requiring close monitoring.
Additive Hypersensitivity Risk Thiazide Diuretics Co-administration is associated with an increased risk of hypersensitivity reactions, particularly in patients with decreased renal function.
Additive Risk Ampicillin / Amoxicillin Concomitant use increases the risk of skin rash.
Timing Separation Rule Aluminum Hydroxide Requires separation of administration by at least 3 hours to prevent decreased absorption of Allopurinol.

Allorin's primary interactions stem from its documented ability to inhibit metabolism, demanding mandatory dosage adjustments for co-administered cytotoxic agents. Furthermore, the official label highlights specific pharmacodynamic risks, such as the increased potential for severe hypersensitivity reactions when combined with certain diuretics or ACE inhibitors. This regulatory information structures the constraints necessary for its co-administration.

Mechanism of Action

How Allorin Works

Allorin and its primary active metabolite, Oxypurinol, operate through the competitive and non-competitive inhibition of the enzyme Xanthine Oxidase (XO), primarily in the liver and intestinal mucosa. Allorin is a structural analog of the natural XO substrate, Hypoxanthine, enabling it to bind to the enzyme’s active site. This action directly interferes with the final two steps of the purine catabolism pathway, suppressing the oxidation of purine precursors into uric acid.

By blocking uric acid synthesis, the drug modulates the flow of the purine pathway, diverting precursors toward the purine salvage pathway. This activity engages a negative feedback loop that concurrently suppresses the overall rate of de novo purine synthesis, providing dual control over production. The core physiological consequence is a sustained reduction in the concentration of uric acid in the bloodstream and tissues, which directly influences urate homeostasis by lowering the saturation point of the substance. This change in saturation facilitates the dissolution of solid urate deposits.

Dosage and Administration Information

How to Use Allorin

Allorin (Allopurinol) is administered through two available administration routes: the oral tablet for long-term chronic management and the intravenous (IV) infusion for patients who cannot tolerate oral intake or require rapid reduction of uric acid, such as in high-risk scenarios.

Oral administration is typically initiated at a low, single daily dose, often 100 mg. The dosage is then titrated in weekly increments based on the patient's urate levels and clinical response, with maintenance doses commonly ranging from 200 mg to 600 mg daily. The maximum recommended daily oral dose is 800 mg.

Administration Requirements

Parameter Standard Usage Guidance
Frequency and Division Doses of 300 mg or less can be taken once daily. Daily doses exceeding 300 mg must be administered in divided doses to maintain steady concentration.
Timing with Food The oral tablet is better tolerated when taken following meals to minimize gastrointestinal irritation.
Special Conditions Patients must maintain high fluid intake sufficient to ensure a daily urinary output of at least two liters (adults).
Renal Adjustment A significant dose reduction is mandatory for patients with impaired kidney function, with the initial dose potentially starting as low as 50 mg daily.

For chronic conditions, the treatment is typically long-term and indefinite. For preventing hyperuricemia related to chemotherapy, use is short-term, beginning 24 to 48 hours before the start of the cytotoxic regimen and concluding once the high-risk period has passed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allorin


Evidence for Use in Chronic Gout and Hyperuricemia

Research examining Allorin for the long-term management of gout and chronic hyperuricemia includes randomized controlled trials (RCTs) and long-term observational cohort studies. Outcomes monitored include changes in the serum uric acid (sUA) biomarker. Studies described patterns showing that measured sUA levels were observed to fall within the target concentration range in research contexts. Research explores patterns where the rate of recurring acute gout attacks appeared to be less frequent in study groups compared to placebo over the periods observed.

However, certainty regarding long-term, non-biomarker outcomes for the broader population appears limited. Many RCTs examining clinical outcomes had follow-up durations that were limited, and long-term data tracking effects on overall health primarily come from observational studies, meaning these effects are not fully established by controlled trials.


Evidence for Preventing Tumor Lysis Syndrome (TLS)

Allorin was studied for use as a preventative measure (prophylaxis) to manage the risk of severe hyperuricemia leading to Tumor Lysis Syndrome (TLS) during certain acute, high-risk medical procedures, such as chemotherapy. Studies monitored outcomes like the prevention of Laboratory Tumor Lysis Syndrome (LTLS). The research reported measurements showing that the rapid rise in serum uric acid levels during the periprocedural period was less pronounced when compared to no intervention. Comparative evidence is lacking from large, modern RCTs that directly compare Allorin with supportive care alone.


What Remains Uncertain in the Research

Research highlights what is known and what is still uncertain. A major limitation is the reliance on surrogate markers, such as sUA levels, rather than consistently tracking hard clinical outcomes like reduced pain or improved function over long periods in gout studies. The follow-up durations were limited in many RCTs. Furthermore, sample sizes were modest in some of the comparative trials, and the evidence quality varies across studies, particularly for the less common indications.

Key Studies & References

  1. Public Assessment Report Scientific discussion Allopurinol Accord (allopurinol) - EMA perspective on indications and efficacy in Europe (Generic Assessment Report)

Frequently Asked Questions (FAQ)

Common questions about Allorin (FAQ)


Q: Can Allorin make you tired or drowsy?

Yes, official product information indicates that drowsiness has been reported as a possible effect for some patients taking allopurinol. Due to this potential effect, regulatory guidelines advise caution when engaging in activities that require full alertness, such as driving or operating machinery.


Q: What happens if you miss a dose of Allorin?

Regulatory guidance suggests taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the general guidance is to skip the missed dose and continue with the regular schedule. Regulatory guidance advises against taking two doses together to compensate for a missed dose.


Q: Are there any long-term side effects from taking Allorin for years?

Regulatory documents list adverse reactions based on their frequency but do not specifically categorize effects as 'long-term' side effects over many years. Because this medication is often prescribed for chronic, indefinite use, patients on long-term treatment are typically monitored by a healthcare professional for potential effects such as changes in liver enzyme levels or kidney function.


Q: Can Allorin interact with herbal teas or remedies?

The official labels prioritize drug-drug interactions. Official patient information suggests that all herbal products, remedies, and supplements should be reviewed with a healthcare professional to check for potential interactions before they are combined with Allorin.


Q: Are there any vitamins or supplements that shouldn't be taken with Allorin?

Official labeling does not provide a specific list of vitamins or supplements to avoid. To ensure there are no unintended interactions, all vitamins and supplements being taken should be reviewed with a healthcare professional.


Q: Does Allorin cause weight gain or weight loss?

Weight change is not listed as a common stand-alone side effect of Allorin in regulatory reports. However, some regulatory reports mention weight loss as a symptom that may accompany more serious underlying effects, such as liver problems.


Q: Are there different forms of Allorin (e.g., tablet, liquid, injection)?

According to official regulatory sources, Allopurinol is approved and available as an oral tablet for long-term management and as an intravenous (IV) injection for use in specific, high-risk clinical settings.


Q: Why does the packaging say to avoid driving when first starting Allorin?

The official product information notes that drowsiness can occasionally occur while taking this medication. Because of the potential for this temporary lack of alertness, the labeling advises caution when performing activities that require concentration, such as driving or operating heavy machinery.


Q: Are there generic versions of Allorin available?

Yes, the medication is widely available by its active ingredient name, allopurinol, which is the generic version. It is also sold under various brand equivalents.


Q: Can Allorin interfere with sleep?

Sleep disturbance is not consistently listed as a common or serious adverse reaction in regulatory labels. However, the reported side effect of drowsiness may indicate a possible effect on the sleep-wake cycle.


Q: Is there a maximum time someone should be on Allorin?

For treating chronic conditions like gout, regulatory documents state that treatment is typically long-term or indefinite. There is no specific maximum duration or time limit specified in the official labels.


Q: Can people with heart conditions take Allorin?

Heart conditions are not listed as an absolute contraindication in the official product label. However, patients with co-existing conditions, particularly chronic kidney disease, require careful dosage adjustment and monitoring. The patient's full health history, including any heart conditions, should be reviewed with the prescribing professional.


Q: Why do doctors often prescribe Allorin for chronic conditions?

Allorin is prescribed for chronic conditions because its mechanism of action is suited for long-term control. It works by inhibiting the enzyme Xanthine Oxidase, which reduces the total amount of uric acid produced in the body, providing sustained metabolic control.


Q: How quickly should I feel better after starting Allorin?

Official information states that a measurable fall in serum uric acid levels usually results within 2 to 3 days of starting treatment, with the full reduction often taking a week or more. It is important to know that an increase in acute gout attacks may sometimes occur during the very early stages of administration.


Q: Is it okay to drink alcohol while taking Allorin?

Official regulatory-derived patient information generally advises consulting a healthcare professional regarding alcohol use. Alcohol may interact with the medication or affect the underlying condition being treated.


Q: Can Allorin affect your stomach or digestion?

Yes, common adverse reactions affecting the digestive system include nausea and diarrhea. The oral tablet is generally better tolerated when taken following a meal, a measure that may help minimize gastrointestinal irritation.


Q: Can Allorin interact with over-the-counter pain relievers like ibuprofen?

While the core regulatory labels do not always list every possible interaction with common over-the-counter pain relievers like NSAIDs or acetaminophen, the co-administration of any over-the-counter medication should be reviewed with a healthcare professional to check for potential risks.


Q: Why is Allorin sometimes taken at night?

The drug is officially prescribed for use once daily or in divided doses. It can be taken at any time of day, but regulatory labels advise taking it after meals to improve tolerance and help prevent stomach irritation.


Q: Can Allorin be taken with food, or does it need to be taken on an empty stomach?

Official administration guidance states that the oral tablet is generally better tolerated when taken following meals. This recommendation is made to help minimize any potential stomach irritation caused by the medication.


Q: Is Allorin generally safe during pregnancy or breastfeeding?

Safety has not been established in human pregnancy, and the active substance is known to pass into breast milk. Regulatory documents state that use is generally restricted to situations where a clinical decision determines the potential benefit outweighs the potential risks.


Q: Is Allorin safe for people with kidney problems?

Patients with impaired kidney function are eligible to use Allorin but require special consideration. Regulatory documents mandate a significant dose reduction and close monitoring of kidney function to minimize the risk of serious side effects, such as hypersensitivity reactions.

How should Allorin be stored and disposed of?

Official Storage and Disposal Instructions for Allopurinol

Allopurinol tablets must be stored according to specific regulatory mandates to maintain product quality.

Storage/Disposal Domain Official Requirement (Label-Based)
Storage Temperature Store at Controlled Room Temperature (20 C to 25 C/68 F to 77 F), protected from excessive heat.
Container Integrity Keep in the original container or a tightly closed container; protect from moisture and light (in a dry place).
Child Safety Mandatory to keep out of the sight and reach of children.
Disposal Instructions Do not flush. Use drug take-back programs or mix with an undesirable substance (e.g., coffee grounds) and place in a sealed container for the household trash.

These storage conditions are essential for maintaining the product's labeled stability. Disposal must adhere to local requirements and utilize take-back options where available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allorin found in:

A-Z Index: